Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation
Open Access
- 5 October 2022
- journal article
- research article
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 9, 105-116
- https://doi.org/10.33393/grhta.2022.2412
Abstract
Objective. To assess the cost-effectiveness and economic sustainability of treosulfan plus fludarabine compared with busulfan plus fludarabine as a conditioning treatment for malignant disease prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients in Italy. Method. The two theoretical cohorts of patients aged ≥ 60 years with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) were pooled and followed over time using a partitioned survival model with cycles of 28 days. Patients can transition between a post-HSCT recovery/remission state (Event-Free Survival state, EFS state), a relapsed/progressed disease state, and a death state. A lifetime horizon for cost-effectiveness analysis and a 5-years’ time horizon for budget impact analysis were used. The perspective of the Italian National Health Service was adopted. Utility values were obtained from published sources. Costs included: drug acquisition, HSCT procedure, management and treatment of adverse reactions, graft-versus-host disease (GvHD) and health states, end of life treatment. Discounting of 3% per year was applied for both costs and outcomes according to Italian guidelines. Sensitivity was tested through both one-way and probabilistic analyses. Results. Cost-effectiveness analysis showed that treosulfan is both more effective and less expensive compared with busulfan (+1.11 life-years, +0.96 quality-adjusted life-years per patient and -€ 41,784 per patient). On the side of economic sustainability, the introduction of treosulfan in the market could generate a cumulative decrement of the expense incurred by NHS of about -€ 179,174 over five years. Conclusion. Treosulfan could represent a cost-effective and sustainable treatment alternative from the perspective of the NHS.Keywords
This publication has 16 references indexed in Scilit:
- Economic burden of toxicities associated with treating metastatic melanoma in eight countriesThe European Journal of Health Economics, 2015
- Conditioning regimens for hematopoietic cell transplantation: one size does not fit allBlood, 2014
- Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myelomaHealth and Quality of Life Outcomes, 2014
- An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza studyClinicoEconomics and Outcomes Research, 2013
- Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)European Journal of Cancer, 2012
- The EBMT risk scoreBone Marrow Transplantation, 2011
- Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30Bone Marrow Transplantation, 2011
- Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2010
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinibBritish Journal of Cancer, 2009
- Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving Transplants in Second Remission or Beyond—The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2006